ATMPs: Practical Hurdles Hamper International Regulatory Collaboration

Regulators from the US, EU, Japan and UK discuss the merits of regulatory convergence for cell and gene therapies, but say that practical challenges often limit their ability to align on pharmaceutical regulatory processes.